FIFARMA Regional Observatory
DATA AT THE SERVICE OF EVERYONE
FIFARMA's Regional Observatory is a new data and analysis space for the sector's ecosystem to have the best information for decision making.
FIFARMA makes available to all interested parties this platform that streamlines access to open data from reliable sources, to provide a complete picture of health in the region in one place.
This is a space in constant evolution, at the service of national authorities, companies, unions, academics, and researchers.
EXPLORE THE DASHBOARDS
FIFARMA INNOVATION INDEX
These data dashboards provide an agile visualization of the main health indicators in three dimensions: country profiles, health indicators and health innovation. This project is a FIFARMA and Innos collaboration for the promotion of transparency and evidence-based decision making.
Country Profile
Health
Innovation
Observatory
of Health Regulatory Policy for Latin America
OPRES monitors and analyzes health policies and regulations in order to disseminate, explain and contribute to their improvement. A deliberation scenario in partnership with Innos.
Latest publications
Understanding the dynamics of the health sector requires analysis, science and in-depth discussions. Learn about the latest reports published by FIFARMA and our strategic allies.
Technology Transfer Challenges and Opportunities in the Latinamerican Pharmaceutical Industry
La activación de escenarios de transferencia tecnológica a nivel global se visualiza como un
camino estratégico para impactar positivamente el desarrollo y el fortalecimiento de
capacidades y escenarios para la producción farmacéutica, a través del relacionamiento
colaborativo.
Evaluación de los requisitos del Certificado de Producto Farmacéutico (CPF) para los procesos de registro de medicamentos en la región de las Américas, hacia un acceso más oportuno a los medicamentos y enfoques regulatorios más convergentes
El presente documento brinda una síntesis del análisis de los resultados de la evaluación de los requerimientos y prácticas de aceptación, uso y emisión del Certificado de Producto Farmacéutico
(CPF) como documento clave en los procesos regulatorios de registro de medicamentos
en la región de las Américas, y de la base legal que sustenta su uso.
Assessing the Certificate of Pharmaceutical Product (CPP) requirements for the drug registration processes in the region of the Americas, towards a more timely access to medicines and more convergent regulatory approaches
This document presents a summary of the analysis of the results for the assessment of the
requirements and practices for the acceptance, use and issuance of the Certificate of Pharmaceutical
Product (CPP) as a key document in the regulatory processes of medicine registration in the
region of the Americas, and in the legal basis supporting its use.
Informe Ejecutivo - Evaluación de los requisitos del Certificado de Producto Farmacéutico (CPF) para los procesos de registro de medicamentos en la región de las Américas, hacia un acceso más oportuno a los medicamentos y enfoques regulatorios más convergentes
El presente documento brinda una síntesis del análisis de los resultados de la evaluación de los
requerimientos y prácticas de aceptación, uso y emisión del Certificado de Producto Farmacéutico
(CPF) como documento clave en los procesos regulatorios de registro de medicamentos en la región
de las Américas, y de la base legal que sustenta su uso.
Executive Report - Assessing the Certificate of Pharmaceutical Product (CPP) requirements for the drug registration processes in the region of the Americas, towards a more timely access to medicines and more convergent regulatory approaches
This document presents a summary of the analysis of the results for the assessment of the
requirements and practices for the acceptance, use and issuance of the Certificate of Pharmaceutical
Product (CPP) as a key document in the regulatory processes of medicine registration in the region
of the Americas, and in the legal basis supporting its use.
Recommendations to apply regulatory "reliance" for the evaluation of post-approval changes.
Post-approval changes (PAC) for medicinal products have increased rapidly in recent years, and faster than national regulatory authorities (NRAs) can reliably cope with. This is both a concern and a challenge for Latin American countries. The World Health Organization (WHO) has recently published two documents that will be critical for countries’ regulatory system strengthening activities, including regulatory cooperation, convergence and transparency.
IFPMA Code of Practice 2019 Q&A
IFPMA Code of Practice 2019 Q&A on the 2019 Code update
Principios de Integridad en las Empresas Farmaceúticas
Una iniciativa regional multisectorial para la industria farmacéutica en América Latina, encabezada por Transparencia Internacional, Capítulo Reino Unido (TI-UK), a través del Programa global del sector biofarmacéutico y servicios para la salud.
IFPMA Code of Practice
The IFPMA Code of Practice was first drawn up in 1981, and it was the first one of its kind for any sector. The 2019 version is marked by two important changes: First, several sections have been updated, including the introduction of a ban on gifts and promotional aids (for Rx based medicines) and secondly there has been a shift from a rules-based to a values-based Code.
Principios de Integridad en las Empresas Farmaceúticas
Es una iniciativa regional multisectorial de la industria farmacéutica en América Latina, encabezada por Transparencia Internacional UK. Este documento ha sido diseñado para proporcionar a las empresas farmacéuticas una guía práctica y un punto de referencia en el desarrollo de políticas y procedimientos propios para promover la integridad en sus actividades.
Business Principles for promoting integrity in the Pharmaceutical Sector (Executive summary)
A regional multi-stakeholder initiative for Latin America’s pharmaceutical industry led by Transparency International’s Pharmaceuticals and Healthcare Programme. This document has been designed to provide companies with practical guidance and a reference point for developing their own policies and procedures for promoting integrity.
Business Principles for promoting integrity in the Pharmaceutical Sector
A Regional Multi-stakeholder Initiative for Latin America led by Transparency International UK’s Pharmaceuticals & Healthcare Programme.
Collaborative approaches to attain Healthcare Sustainability in Latin America (Executive Summary)
Attainment of universal health coverage (UHC) has become a priority for Latin America (LA) governments, but increasing coverage unavoidably comes with rising healthcare costs and the challenge of fostering efficiencies.
COVID-19 Policy Environment and the Importance of Health Economy in Latin America
Latin America was among the regions hit hardest by the COVID-19 pandemic in terms of health and the economy. As every disruption has potential for societal progress, this report provides insights into the status of theHealthEconomies and on health sector reforms in selected Latin American (LatAm) countries. These exemplary cases can serve as an evidence base to support and guide policy work on further enhancing resilience in the transition to the post-COVID era. The report strengthens the view of health as an investment rather than a cost for society, which pays off in the future and offers a considerable return on investment for society as a whole.
Soluciones propuestas para lograr la Sostenibilidad de la Salud en América Latina
El logro de la cobertura universal de salud (CUS) se ha convertido en una prioridad para los gobiernos de América Latina (AL), pero aumentar la cobertura inevitablemente conlleva el aumento de los costos de salud y el desafío para fomentar la eficiencia.
Explore the databases
Consult the data sources that FIFARMA and its partners make available to researchers, decision makers and authorities in the region.
Contact for researchers
If you have any questions, comments, or requests for information, please contact our team:
Email: info@fifarma.org